Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001238259 | SCV001411060 | likely pathogenic | not provided | 2019-11-05 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MYO7A are known to be pathogenic (PMID: 8900236, 25404053). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Disruption of this splice site has been observed in individual(s) with Usher syndrome (PMID: 28041643). This variant is not present in population databases (ExAC no frequency). This sequence change affects an acceptor splice site in intron 23 of the MYO7A gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. |
New York Genome Center | RCV001839034 | SCV002099273 | uncertain significance | Usher syndrome type 1 | 2021-04-30 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001834062 | SCV002086647 | likely pathogenic | Usher syndrome type 1B | 2020-07-01 | no assertion criteria provided | clinical testing |